Swiss Re has flagged that the changing trajectory of cancer — from a high-severity acute disease toward a higher-incidence, longer-duration condition — is reshaping core assumptions across life and health insurance portfolios, with screening advances and new diagnostic tools recasting how the risk is priced.
Around 20 million people are diagnosed with cancer each year worldwide, and roughly 10 million die from the disease annually, the reinsurer noted. By 2050, annual case counts are tipped to climb to 35 million on the back of aging populations, lifestyle factors and environmental pressures.
Survival, meanwhile, is improving. Swiss Re said the burden is moving away from acute mortality toward longer disease duration and higher lifetime healthcare use, shifting the exposure profile for insurance carriers.
The shift echoes earlier commentary from peer Munich Re, whose Life Science Report has framed cancer as moving toward a chronic, treatable disease.
Dr. Brad Heltemes, VP and medical director of R&D at Munich Re, previously noted that the changes are expected to lift life expectancy and weigh unfavorably on longevity markets, with disease classifications increasingly migrating toward genetic and molecular profiles.
Swiss Re pointed to early detection and primary prevention as the central levers behind improving outcomes, with cancers caught at earlier stages typically more treatable and tied to higher survival.
Screening programs have already lowered mortality in several disease types. Cervical cancer incidence and mortality in Finland have fallen by around 80% over roughly 60 years, while the US and Australia have posted a 50% drop in incidence.
In the US, stool-based colorectal screening has been linked to a 33% lower risk of death from the disease.
The blind spots remain stark. About 70% of US cancer deaths are tied to types without established screening programs, including pancreatic, ovarian and esophageal cancers.
Artificial intelligence is now in play across imaging and biomarker analysis, supporting diagnosis and flagging higher-risk individuals.
Multi-cancer early detection (MCED) tests, which look for several cancers from a single blood sample, sit alongside that as another emerging tool — though Swiss Re cautioned that their large-scale impact on mortality has yet to be established and positive results still need confirmatory diagnostics.
For insurance carriers, the new tools could drive earlier and more frequent testing across populations but may also feed overdiagnosis of low-risk or indolent cancers.
The reshaping of cancer risk is landing as the global mortality protection gap continues to widen. Swiss Re Institute's Mortality Resilience Index ticked up to 44.4% in 2024 from 43.6%, even as the protection gap rose to $432 billion in premium-equivalent terms — up from $423 billion in 2023 and $321 billion in 2014.
The population aged 65 and older in high-income countries is projected to grow by about 35% by 2050, lifting demand for retirement, longevity and health-related cover — a backdrop against which Swiss Re said stage-at-diagnosis models are losing reliability as earlier detection pulls a wider mix of cases into early stages.
